tbuckley/cabot-search huggingface dataset:
Single-cell RNA-Seq analysis of molecular changes during radiation-induced skin injury: the involvement of Nur77
Authors: Tao Yan, Ping Yang, Hao Bai, Bin Song, Yulan Liu, Jiajia Wang, Yuehua Zhang, Wenling Tu, Daojiang Yu, Shuyu Zhang
Journal: Theranostics (2024)

Ionizing radiation has been widely used in industry, medicine, military and agriculture. Radiation-induced skin injury is a significant concern in the context of radiotherapy and accidental exposure to radiation. The molecular changes at the single-cell level and intercellular communications during radiation-induced skin injury are not well understood.
Hypoxia-induced TGFBI maintains glioma stem cells by stabilizing EphA2
Authors: Zirong Chen, Junhong Wang, Peng Peng, Guohao Liu, Minhai Dong, Xiaolin Zhang, Yang Zhang, Xue Yang, Lijun Wan, Wang Xiang, Suojun Zhang, Bin Zhang, Qiuxia Wu, Xingjiang Yu, Feng Wan
Journal: Theranostics (2024)

Glioma stem cells (GSCs) have emerged as pivotal drivers of tumor malignancy, sustained by various microenvironmental factors, including immune molecules and hypoxia. In our previous study, we elucidated the significant role of transforming growth factor beta-induced protein (TGFBI), a protein secreted by M2-like tumor-associated macrophages, in promoting the malignant behavior of glioblastoma (GBM) under normoxic conditions. Building upon these findings, the objective of this study was to comprehensively explore the crucial role and underlying mechanisms of autocrine TGFBI in GSCs under hypoxic conditions.
Highly potent and selective PPARδ agonist reverses memory deficits in mouse models of Alzheimer's disease
Authors: Hyeon Jeong Kim, Haelee Kim, Jaeyoung Song, Jun Young Hong, Elijah Hwejin Lee, Ashwini M Londhe, Ji Won Choi, Sun Jun Park, Eunseok Oh, Heeseok Yoon, Hoosang Hwang, Dongyup Hahn, Kyungjin Jung, Sugyeong Kwon, Tara Man Kadayat, Min Jung Ma, Jeongmin Joo, Jina Kim, Jae Hyun Bae, Hayoung Hwang, Ae Nim Pae, Sung Jin Cho, Jong-Hyun Park, Jungwook Chin, Heonjoong Kang, Ki Duk Park
Journal: Theranostics (2024)

Alzheimer's disease (AD) is a progressive neurodegenerative disease accompanied by neurotoxicity, excessive inflammation, and cognitive impairment. The peroxisome proliferator-activated receptor (PPAR) δ is a potential target for AD. However, its regulatory mechanisms and therapeutic potential in AD remain unclear. We aimed to investigate if the activation of PPARδ using a highly selective and potent agonist could provide an effective therapeutic strategy against AD.
Viscoelasticity of Hyaluronic Acid Hydrogels Regulates Human Pluripotent Stem Cell‐derived Spinal Cord Organoid Patterning and Vascularization
Authors: Xingchi Chen, Chang Liu, Garrett McDaniel, Olivia Zeng, Jamel Ali, Yi Zhou, Xueju Wang, Tristan Driscoll, Changchun Zeng, Yan Li
Journal: Advanced Healthcare Materials (2024)

Abstract Recently, it has been recognized that natural extracellular matrix (ECM) and tissues are viscoelastic, while only elastic properties have been investigated in the past. How the viscoelastic matrix regulates stem cell patterning is critical for cell‐ECM mechano‐transduction. Here, this study fabricated different methacrylated hyaluronic acid (HA) hydrogels using covalent cross–linking, consisting of two gels with similar elasticity (stiffness) but different viscoelasticity, and two gels with similar viscoelasticity but different elasticity (stiffness). Meanwhile, a second set of dual network hydrogels are fabricated containing both covalent and coordinated cross–links. Human spinal cord organoid (hSCO) patterning in HA hydrogels and co‐culture with isogenic human blood vessel organoids (hBVOs) are investigated. The viscoelastic hydrogels promote regional hSCO patterning compared to the elastic hydrogels. More viscoelastic hydrogels can promote dorsal marker expression, while softer hydrogels result in higher interneuron marker expression. The effects of viscoelastic properties of the hydrogels become more dominant than the stiffness effects in the co‐culture of hSCOs and hBVOs. In addition, more viscoelastic hydrogels can lead to more Yes‐associated protein nuclear translocation, revealing the mechanism of cell‐ECM mechano‐transduction. This research provides insights into viscoelastic behaviors of the hydrogels during human organoid patterning with ECM‐mimicking in vitro microenvironments for applications in regenerative medicine.
Sexual health-related psychological and emotional life after allogeneic haematopoietic stem-cell transplantation
Authors: Tamim Alsuliman, Lugien Alasadi, Alice Polomeni, Antoine Capes, Zinaida Peric, Andrea Linke, Hélène Schoemans, Florent Malard, Yves Chalandon, Mohamad Mohty
Journal: The Lancet Haematology (2024)
Sexual health and emotional wellbeing of patients with haematological malignancies: general review
Authors: Tamim Alsuliman, Reyes María Martín Rojas, Nour Moukalled, Eolia Brissot, Laurence Quarez-Blaise, Zora Marjanovic, Didier Blaise, Danielle Murphy, Melissa Logue, Bipin N Savani, Mohamad Mohty
Journal: The Lancet Haematology (2024)
Colon-specific controlled release of oral liposomes for enhanced chemo-immunotherapy against colorectal cancer
Authors: Mengya Niu, Yihan Pei, Tiantian Jin, Junxiu Li, Liming Bai, Cuixia Zheng, Qingling Song, Hongjuan Zhao, Yun Zhang, Lei Wang
Journal: Acta Pharmaceutica Sinica B (2024)

A colon-specific drug delivery system has great potential for the oral administration of colorectal cancer. However, the uncontrollable
Single-atom materials boosting wearable orthogonal uric acid detection
Authors: Shichao Ding, Sitao Li, Zhaoyuan Lyu, Jiachi Zhou, Selene Tang, Lingzhe Fang, Wenjie Zang, Pengtao Zhang, Sunjae Kim, Tao Li, Xiaoqing Pan, Dan Du, Yuehe Lin, Joseph Wang
Journal: Med-X (2024)
In‐hospital course of patients with heart failure with improved ejection fraction in the <scp>DELIVER</scp> trial
Authors: Maria A Pabon, Muthiah Vaduganathan, Brian L. Claggett, Safia Chatur, Sara Siqueira, Pablo Marti‐Castellote, Rudolf A. de Boer, Adrian F. Hernandez, Silvio E. Inzucchi, Mikhail N. Kosiborod, Carolyn S.P. Lam, Felipe Martinez, Sanjiv J. Shah, Akshay S. Desai, Pardeep S. Jhund, John J.V. McMurray, Scott D. Solomon, Orly Vardeny
Journal: European Journal of Heart Failure (2024)
Current emerging therapeutic targets and clinical investigational agents for schizophrenia: Challenges and opportunities
Authors: Na Ye, Qi Wang, Yue Li, Xuechu Zhen
Journal: Medicinal Research Reviews (2024)

Abstract Since the first discovery of antipsychotics in the 1950s, targeting dopaminergic drugs has manifested to well manage the positive symptoms of schizophrenia with limited efficacy for the negative and cognitive symptoms. In past decades, extensive efforts have been undertaken towards the development of innovative agents that can effectively stabilize the dopamine and serotonin systems or target to nondopaminergic pathways, leading to various promising drug candidates entering into clinical trials. Notably, the sigma‐2, 5‐HT 2A , and α 1A receptor antagonist roluperidone, as well as a fixed‐dose combination of the M 1/4 receptor agonist KarXT, have been submitted for NDA applications. The dual agonist ulotaront, which targets TAAR1 and 5‐HT 1A receptors, and the GlyT1 inhibitor iclepertin have advanced into phase 3 clinical trials. Nevertheless, satisfactory therapeutic strategies for schizophrenia remain elusive. This review highlights current clinical endeavors in developing novel chemical small‐molecule entities and fixed‐dose combinations for the treatment of schizophrenia since 2017, thus facilitating the efficient development of the next generation of antipsychotics.
Aetiology and clinical manifestations of patients with non‐dilated left ventricular cardiomyopathy
Authors: Emanuele Monda, Anna Murredda, Marta Rubino, Gaetano Diana, Giuseppe Palmiero, Federica Verrillo, Chiara Cirillo, Annapaola Cirillo, Adelaide Fusco, Giulia Frisso, Martina Caiazza, Giuseppe Limongelli
Journal: European Journal of Heart Failure (2024)
Predicting survival after Impella implantation in patients with cardiogenic shock: The J‐<scp>PVAD</scp> risk score
Authors: Toru Kondo, Tomo Yoshizumi, Ryota Morimoto, Takahiro Imaizumi, Shingo Kazama, Hiroaki Hiraiwa, Takahiro Okumura, Toyoaki Murohara, Masato Mutsuga
Journal: European Journal of Heart Failure (2024)
Harms with placebo in trials of biological therapies and small molecules as induction therapy in inflammatory bowel disease: a systematic review and meta-analysis
Authors: Shahida Din, Jonathan Segal, Jonathan Blackwell, Beatriz Gros, Christopher J Black, Alexander C Ford
Journal: The Lancet. Gastroenterology & hepatology (2024)

Randomised placebo-controlled trials are the gold standard to assess novel drugs in ulcerative colitis and Crohn's disease. However, there might be risks associated with receiving placebo. We aimed to examine the harms associated with receiving placebo in trials of licensed biologics and small molecules for the induction of remission in ulcerative colitis and luminal Crohn's disease in a meta-analysis.
Harms with placebo in trials of biological therapies and small molecules as maintenance therapy in inflammatory bowel disease: a systematic review and meta-analysis
Authors: Beatriz Gros, Jonathan Blackwell, Jonathan Segal, Christopher J Black, Alexander C Ford, Shahida Din
Journal: The Lancet. Gastroenterology & hepatology (2024)

Randomised placebo-controlled trials for the induction of inflammatory bowel disease (IBD) remission involve potential harms to those receiving placebo. Whether these harms are also apparent with placebo during maintenance of remission trials in IBD is unclear. We aimed to examine the potential harms associated with receiving placebo in trials of licensed biologics and small molecules for maintenance of remission of ulcerative colitis and luminal Crohn's disease in a meta-analysis.
Testosterone Recovery Following Androgen Suppression and Prostate Radiotherapy (TRANSPORT): A Pooled Analysis of Five Randomized Trials from the Meta-Analysis of Randomized Trials in Cancer of the Prostate (MARCAP) Consortium
Authors: Wee Loon Ong, Tahmineh Romero, Soumyajit Roy, John Nikitas, David Joseph, Almudena Zapatero, Shawn Malone, Scott C Morgan, Michael L Steinberg, Luca F Valle, Nicholas G Zaorsky, Ting Martin Ma, Matthew B Rettig, Nicholas Nickols, Tommy Jiang, Robert E Reiter, Sriram V Eleswarapu, Xavier Maldonado, Yilun Sun, Paul L Nguyen, Jeremy L Millar, Jarad M Martin, Daniel E Spratt, Amar U Kishan
Journal: European Urology (2024)
Prostate Cancer–related Events in Patients with Synchronous Metastatic Hormone-sensitive Prostate Cancer Treated with Androgen Deprivation Therapy with and Without Concurrent Radiation Therapy to the Prostate; Data from the HORRAD Trial
Authors: Liselotte M S Boevé, Maarten C C M Hulshof, Paul C M S Verhagen, Jos W R Twisk, Wim P J Witjes, Peter de Vries, R Jeroen A van Moorselaar, André N Vis, George van Andel
Journal: European Urology (2024)
Efficacy and Safety of Intravenous Secukinumab for the Treatment of Active Psoriatic Arthritis: Results From the Randomized, Placebo‐Controlled Phase <scp>III INVIGORATE</scp>‐2 Study
Authors: Alan Kivitz, Liliana Sedova, Melvin Churchill, Roshan Kotha, Atul Singhal, Alexander Torres, Guillermo Valenzuela, Sarah Whelan, Thomas Dumortier, Xuan Zhu, Ruvie Martin, Luminita Pricop
Journal: Arthritis & Rheumatology (2024)

Objective To evaluate the efficacy and safety of intravenous (IV) secukinumab in patients with active psoriatic arthritis (PsA). Methods INVIGORATE‐2 (NCT04209205) is a randomized, placebo‐controlled, phase III trial. Patients with active PsA were randomized 1:1 to receive IV secukinumab (6 mg/kg at baseline followed by 3 mg/kg every 4 weeks [q4w]) or placebo. At Week 16, patients randomized to placebo were switched to IV secukinumab (3 mg/kg q4w), and patients receiving IV secukinumab continued treatment through Week 52. The primary efficacy endpoint was achievement of American College of Rheumatology (ACR) 50 response at Week 16. Efficacy and safety were evaluated through Weeks 52 and 60, respectively. Results Among 191 patients randomized to IV secukinumab and 190 to placebo/IV secukinumab, 177 (92.7%) and 170 (89.5%) completed the entire study period, respectively. A significantly higher proportion of patients receiving IV secukinumab vs placebo achieved ACR50 at Week 16 (31.4% vs 6.3%; adjusted P &lt;.0001). All secondary efficacy endpoints were met at Week 16 (all adjusted P &lt;.05 using the predefined hypothesis‐testing hierarchy). Patients who switched from placebo to secukinumab at Week 16 showed rapid improvements in ACR50 response rates; by Week 52, both treatment arms experienced similar improvements in efficacy outcomes. No new or unexpected safety signals were observed with IV secukinumab. One death was reported in the placebo group prior to Week 16. Conclusion IV secukinumab led to rapid and sustained improvements in clinical measures of PsA, and the safety profile was consistent with that of secukinumab administered subcutaneously.
Weight loss after initiating anti‐obesity medications and gout among overweight and obesity individuals: a population‐based cohort study
Authors: Jie Wei, Yilun Wang, Nicola Dalbeth, Junqing Xie, Jing Wu, Chao Zeng, Guanghua Lei, Yuqing Zhang
Journal: Arthritis & Rheumatology (2024)

Weight loss is conditionally recommended for gout management; however, its impact on incident gout and recurrent gout flares among individuals who were overweight and obese remains unknown. We investigate the relationship between weight loss rate following treatment with anti-obesity medications and the risk of incident gout and recurrent gout flares among individuals who were overweight or obese.
Efficacy and Safety of Intravenous Secukinumab in Patients With Active Axial Spondyloarthritis: Results From the Randomized, Placebo‐Controlled, Phase <scp>III INVIGORATE</scp>‐1 Study
Authors: Atul Deodhar, Jerzy Supronik, Alan Kivitz, Guillermo Valenzuela, Karen Kapur, Susanne Rohrer, Eva Dokoupilova, Hanno B. Richards, Karel Pavelka
Journal: Arthritis & Rheumatology (2024)

Objective To assess the efficacy and safety of intravenous (IV) secukinumab for the treatment of adults with active axial spondyloarthritis (axSpA) in INVIGORATE‐1. Methods INVIGORATE‐1 (NCT04156620) was a randomized, double‐blind, parallel‐group, phase III trial in patients with active axSpA (either radiographic or non‐radiographic). Patients were randomized 1:1 to receive IV secukinumab (6 mg/kg at baseline followed by 3 mg/kg every 4 weeks) or IV placebo for 16 weeks. After Week 16, patients randomized to placebo were switched to IV secukinumab (3 mg/kg every 4 weeks), while patients randomized to secukinumab continued treatment through Week 52. The primary endpoint was Assessment of SpondyloArthritis international Society (ASAS40) response at Week 16. Safety was evaluated through Week 60. Results Among patients initially randomized to IV secukinumab (n = 264) or placebo (n = 262), 86.0% and 88.9% completed the entire 60‐week study period, respectively. A higher proportion of patients receiving secukinumab vs placebo met the primary endpoint (ASAS40 response) at Week 16 (40.9% vs 22.9%; P &lt;.0001). By Week 24, patients who switched from placebo to secukinumab at Week 16 achieved ASAS40 response rates comparable to those in patients originally randomized to secukinumab. All secondary efficacy endpoints were met at Week 16, and responses were sustained through Week 52. No new or unexpected safety signals were observed with IV secukinumab. Conclusion IV secukinumab was effective for the treatment of adults with active axSpA over 52 weeks. The safety profile was consistent with that in previous reports on subcutaneous secukinumab.
American Radium Society™ Appropriate Use Criteria on Cardiac Toxicity Prevention and Management After Thoracic Radiotherapy
Authors: Arya Amini, Vlad G Zaha, Eman Hamad, Pamela K Woodard, Andreas Rimner, Joe Y Chang, Stephen G Chun, Jessica Donington, Martin J Edelman, Matthew A Gubens, Kristin A Higgins, Puneeth Iyengar, Aditya Juloori, Benjamin Movsas, Matthew S Ning, Henry S Park, George Rodrigues, Andrea Wolf, Charles B Simone
Journal: Journal of Thoracic Oncology (2024)
Double-stranded DNA enhances platelet activation, thrombosis, and myocardial injury via cyclic GMP-AMP synthase
Authors: Wei Zhang, Yan Zhang, Liping Han, Tao Bo, Zhiyong Qi, Haoxuan Zhong, Huajie Xu, Liang Hu, She Chen, Si Zhang
Journal: Cardiovascular Research (2024)

Elevated dsDNA levels in STEMI patients are associated with increased infarct size and worse clinical outcomes. However, the direct effect of dsDNA on platelet activation remains unclear. This study aims to investigate the direct influence of dsDNA on platelet activation, thrombosis, and the underlying mechanisms.
GPCR Biosensors to Study Conformational Dynamics and Signaling in Drug Discovery
Authors: Victoria R. Saca, Colin Burdette, Thomas P. Sakmar
Journal: The Annual Review of Pharmacology and Toxicology (2025)

G protein-coupled receptors (GPCRs) are a superfamily of transmembrane signal transducers that facilitate the flow of chemical signals across membranes. GPCRs are a desirable class of drug targets, and the activation and deactivation dynamics of these receptors are widely studied. Multidisciplinary approaches for studying GPCRs, such as downstream biochemical signaling assays, cryo-electron microscopy structural determinations, and molecular dynamics simulations, have provided insights concerning conformational dynamics and signaling mechanisms. However, new approaches including biosensors that use luminescence- and fluorescence-based readouts have been developed to investigate GPCR-related protein interactions and dynamics directly in cellular environments. Luminescence- and fluorescence-based readout approaches have also included the development of GPCR biosensor platforms that utilize enabling technologies to facilitate multiplexing and miniaturization. General principles underlying the biosensor platforms and technologies include scalability, orthogonality, and kinetic resolution. Further application and development of GPCR biosensors could facilitate hit identification in drug discovery campaigns. The goals of this review are to summarize developments in the field of GPCR-related biosensors and to discuss the current available technologies.
A new perspective in intestinal microecology: lifting the veil of exercise regulation of cardiometabolic diseases
Authors: Can Gao, Jinwen Wei, Changxu Lu, Lijie Wang, Dan Dong, Mingli Sun
Journal: Gut Microbes (2024)

Cardiometabolic diseases (CMDs), encompassing cardiovascular and metabolic dysfunctions, characterized by insulin resistance, dyslipidemia, hepatic steatosis, and inflammation, have been identified with boosting morbidity and mortality due to the dearth of efficacious therapeutic interventions. In recent years, studies have shown that variations in gut microbiota and its own metabolites can influence the occurrence of CMDs. Intriguingly, the composition and function of the gut microbiota are susceptible to exercise patterns, thus affecting inflammatory, immune, and metabolic responses within the host. In this review, we introduce the key mechanisms of intestinal microecology involved in the onset and development of CMDs, discuss the relationship between exercise and intestinal microecology, and then analyze the role of intestinal microecology in the beneficial effects of exercise on CMDs, aiming at elucidating the gut-heart axis mechanisms of exercise mediated protective effect on CMDs, building avenues for the application of exercise in the management of CMDs.
Intestinal deguelin drives resistance to acetaminophen-induced hepatotoxicity in female mice
Authors: Shenhai Gong, Yunong Zeng, Ze Wang, Yanru Li, Rong Wu, Lei Li, Hongbin Hu, Ping Qin, Zhichao Yu, Xintao Huang, Peiheng Guo, Hong Yang, Yi He, Zhibin Zhao, Weidong Xiao, Xiaoshan Zhao, Lei Gao, Shumin Cai, Zhenhua Zeng
Journal: Gut Microbes (2024)

Acetaminophen (APAP) overdose is a leading cause of drug-induced liver injury (DILI), with gender-specific differences in susceptibility. However, the mechanism underlying this phenomenon remains unclear. Our study reveals that the gender-specific differences in susceptibility to APAP-induced hepatotoxicity are due to differences in the gut microbiota. Through microbial multi-omics and cultivation, we observed increased gut microbiota-derived deguelin content in both women and female mice. Administration of deguelin was capable of alleviating hepatotoxicity in APAP-treated male mice, and this protective effect was associated with the inhibition of hepatocyte oxidative stress. Mechanistically, deguelin reduced the expression of thyrotropin receptor (TSHR) in hepatocytes with APAP treatment through direct interaction. Pharmacologic suppression of TSHR expression using ML224 significantly increased hepatic glutathione (GSH) in APAP-treated male mice. These findings suggest that gut microbiota-derived deguelin plays a crucial role in reducing APAP-induced hepatotoxicity in female mice, offering new insights into therapeutic strategies for DILI.
1632P Impact of androgen pathway inhibitors on cognitive function in elderly patients with metastatic prostate cancer: Results from the COG-PRO trial
Authors: A. Boué, G. Baciarello, E. Meyer, F. Christy, N. Allouache, R. Ratta, P-E. Brachet, E. Guerdoux, A. Darlix, M. Boone, S. Gouerant, A. Leconte, J. Lequesne, B. Clarisse, K. Fizazi, M. Lange, F. Joly Lobbedez
Journal: Annals of Oncology (2024)
Targeted V-type peptide-decorated nanoparticles prevent colitis by inhibiting endosomal TLR signaling and modulating intestinal macrophage polarization
Authors: Tongxuan Li, Qianqian Li, Sixia Liu, Jiazhu Cao, Jian Mei, Jiameng Gong, Jiugeng Chen, Xiaoyu Wang, Rui Zhang, Xiaomeng Li, Qian Wang, Hefan Zhang, Bangmao Wang, Hailong Cao, Hong Yang, Shan-Yu Fung
Journal: Biomaterials (2024)
1732P Primary pulmonary sarcoma: A EURACAN project
Authors: S. Collaud, T. Stork, D. Adámková Krákorová, C. Aigner, I. Bravio, A. Brunello, H. Clermidy, L. De Cock, N. Girard, A. Mariuk-Jarema, R. Lefering, G. Marquina Ospina, I. Mykoliuk, N. Penel, H-U. Schildhaus, S. Strippoli, B. Vincenzi, S. Watson, J-Y. Blay, S. Bauer
Journal: Annals of Oncology (2024)
1736P An open label phase IIa study evaluating the preliminary efficacy of intratumoural tigilanol tiglate (TT) in advanced and/or metastatic soft tissue sarcoma (STS)
Authors: E.K. Bartlett, D. Li, S. Shemla, C.E. Ariyan, S. Dickinson, A. Crago, G. Li, N. Agaram, S.P. D'Angelo, R.G. Maki, S. Singer, W.D. Tap, C.M. Kelly
Journal: Annals of Oncology (2024)
1725MO IMMUNOSARC II master trial (phase II of sunitinib and nivolumab): Results from the clear cell sarcoma (CCS) cohort: A GEIS, ISG, and UCL study
Authors: J. Martin-Broto, E. Palmerini, C.M. Valverde Morales, A. Sebio Garcia, A. Redondo, S. Stacchiotti, S. Strauss, G. Grignani, S. Aliberti, R.P. Diaz Beveridge, E. Gonzalez Billalabeitia, J. Cruz Jurado, A.M. Gutierrez Garcia, P. Ledesma, D. Da Silva Moura, N. Hindi Muñiz
Journal: Annals of Oncology (2024)
1739P Linnovate: A phase I/II study of safety/efficacy using lurbinectedin combined with ipilimumab and nivolumab for advanced soft tissue sarcoma (NCT05876715) - Interim analysis of phase I part
Authors: E.M. Gordon, S.P. Chawla, N. Omelchenko, S. Jeffrey, A.D. Agarwal, N.S. Chawla, V.S. Chua Alcala, D. Quon, S. Wong
Journal: Annals of Oncology (2024)
1738P Results from the conference on challenges in sarcoma (CCS) 2024
Authors: C.A. Rothermundt, S.B. Hofer, C. Pauli, A. Miah, W.G. Kunz, E. Wardelmann, P. Rutkowski, P. Reichardt, H. Gelderblom, R.L. Haas, C. Fotopoulou, K. Scheinemann, D. Andreou
Journal: Annals of Oncology (2024)
1734P Evaluation of nivolumab in cutaneous angiosarcoma management: The ANGIOCHECK study
Authors: Y. Fujisawa, K. Namikawa, S. Ishitsuki, K. Yoshino, T. Isei, H. Kato, T. Yanagi, Y. Yamamoto, H. Uchi, A. Otsuka
Journal: Annals of Oncology (2024)
1695P Phase I LITESPARK-018: Dose escalation study of belzutifan in advanced pretreated clear cell renal cell carcinoma (ccRCC)
Authors: U.N. Vaishampayan, A.J. Zurita Saavedra, K. Beckermann, A. Chain, D. Vickery, Y. Zhang, R. Perini, D.F. McDermott
Journal: Annals of Oncology (2024)